Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy

Abstract: Despite the prominent effects of BCR-ABL tyrosine kinase inhibitors (TKI) therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML) and thus low incidence of blastic transformation, blast phase (BP)-CML remains a major therapeutic challenge in the TKI era. The “gatekeeper” mutation T315I in BCR-ABL1 kinase, which often coupled with a poor prognosis, is quite common and resistant to all TKIs except for ponatinib. The occurrence of T315I mutation in BP-CML makes the situation more complex. Anti-CD19 chimeric antigen receptor T cell (CAR-T) technology is a new immunotherapy which has significantly improved the efficacy of B cell hematologic malignances. Here we report a lymphoid BP-CML patient harboring T315I mutation who achieved complete molecular remission and returned to chronic phase by anti-CD19 CAR-T therapy. Our study provides a new therapeutic strategy for patients in BP-CML.

Keywords: anti-CD19 CAR-T, BP-CML, BCR-ABL1, T315I

Introduction
Chronic myeloid leukemia (CML), accounting for 15–20% of all leukemia cases in adults, is a malignant clonal hematological disease that makes the myeloid neoplastic cells proliferation out of control.1 It is characterized by the formation of a fusion gene, BCR-ABL1, by ABL1 gene on chromosome 9 and BCR gene on chromosome 22, which results in the expression of oncoprotein BCR-ABL1. CML has a natural history of 3 distinct stages: chronic phase (CP), accelerated phase (AP), and blast phase (BP). The final transformation of CML can result in myeloblastic (50%) or lymphoblastic (25%) phenotypes, with the remaining 25% comprising bi-phenotypic or undifferentiated blasts.2,3 The biologic basis of the progression from chronic phase through accelerated phase to blast crisis is poorly understood. It is now generally accepted that it is the consequence of continued BCR-ABL activity leading to genetic instability, DNA damage, and impaired DNA repair.4,5 This progression usually leads to patient death in 3 years.6 Reports show the median overall survival and failure-free survival of BP-CML was 12 months and 5 months, respectively.7 Treatment with TKIs has reduced the rate of progression to BP and improved survival in blast crisis (BC) modestly. However, the efficacy of TKI monotherapy in BP-CML is quite unsatisfactory, probably due to an inability to eliminate the leukemic clone8 and rapid onset of BCR-ABL1 mutations which are resistant to TKI monotherapy.9,10
Furthermore, even if favorable responses can be achieved with a combination therapy of TKI and conventional chemotherapy in some patients, their responses are usually transitory. The combination treatment may bring more side effects and possibly not feasible for elderly or unfit patients. In most cases, TKIs alone or in combination with conventional chemotherapy provide a possible bridge to bone marrow transplant. Nowadays, allogeneic bone marrow transplant remains the only curative option for CML patients, but only in a minority of eligible patients with a compatible donor. Thus, there is yet to be an ideal method for managing patients in this phase. Further studies are urgently needed to improve therapeutic efficacy and long-term outcome.

Since its first report in 2006, CAR-T, as a new immunotherapy, has been widely used for various diseases, especially in the treatment of hematological malignancies, in which CAR-T has achieved unprecedented success. The most successful results were mainly from the anti-CD19 CAR-T therapy, which significantly improved the clinical efficacy of B-cell malignances. As a result, it was named “the top ten scientific breakthrough in 2013” by Science along with the “Immune Monitoring Point Blocking Antibody Therapy”. CAR-T cells could bypass the normal activation pathway, transcend the restriction of MHC molecules, partially overcome the immune escape of cancer cells, and more efficiently kill cancer cells. At the same time, as CAR-T cells have high affinity for specific tumor antigens, they can kill tumor cells expressing these antigens efficiently. Compared with conventional chemotherapy regimens, CAR-T cells enhance the killing ability of specific targets and reduce treatment-related toxicity. Therefore, it is of great significance to explore the efficacy and safety of anti-CD19 CAR-T cell therapy for lymphoid BP-CML patients.

In this paper, we report a lymphoid BP-CML patient harboring T315I mutation in BCR-ABL1 who returned to chronic phase and achieved complete molecular remission with anti-CD19 CAR-T therapy. As far as we know, this is the first case of a T315I-bearing lymphoid BP-CML patient displaying satisfactory response to anti-CD19 CAR-T therapy.

**Case Report**

A 60-year-old male patient was found to have leukocytosis in a routine physical examination in 2015. He did not attach much importance to it. However, on November 13, 2016, he was admitted to our hospital complaining of limb pain and being emaciated for half a year. Blood tests showed a high white blood cell count of 130x10^9/L, while the platelet count was 123x10^9/L and hemoglobin level was 109 g/L. Spleen size was normal. Bone marrow examination and flow cytometry suggested chronic myelogenous leukemia in chronic phase. Cytogenetics revealed Philadelphia chromosome was positive. FISH analysis detected that the BCR-ABL1 expression was 95%. He was thus diagnosed with CP-CML, with low risk according to the Sokal score 0.78.

The patient was given imatinib (400 mg/d) starting from January 13, 2017, but resistance occurred quickly after half a year. Gene sequencing showed Y253H mutation in the ABL1 kinase domain (Figure 1). As a result, dasatinib (100mg/d) was given instead. On February 23, 2018, bone marrow examination revealed a blast crisis, with 55% of leukemic blasts that were CD19+/CD10+/CD34+/CD22+/CD79a+/CD3-/CD56-/CD16-/CD13-/CD33+. The total percentage of cells expressing CD19 was 57%. No additional chromosomal alterations were identified. Moreover, T315I mutation was identified in Sanger sequencing (Figure 1). The patient was then given induction chemotherapy with the daunorubicin, L-asparaginase, prednisone, and cyclophosphamide (DVCLP) regimen in combination with dasatinib (100mg/d) for two courses of treatment on March 5 and April 23, 2018, respectively. It was shown that the BCR-ABL1 level decreased from 50.76% (IS) to 4.12% (IS) after chemotherapy in combination with dasatinib, then increased to 10.82% (IS) 3 months later (Figure 2).

Subsequently, on July 7, 2018, the patient received an infusion of anti-CD19 CAR-T cells that had been activated ex vivo with anti-CD3/CD28 antibody-coated beads and transduced with a lentiviral vector containing the anti-CD19 CAR transgene. The total dose was 1.6x10^6 CAR-positive T-cells/kg, given over 3 consecutive days. Meanwhile, the patient was not given dasatinib during the CAR-T therapy since he was resistant to dasatinib. No immediate infusion-related toxicity was observed, but he developed rigor and fever (38°C) by day +10, with C-reactive protein (CRP 2.65 mg/L), cytokine levels (Figure 3), and ferritin (960 ng/mL) increasing significantly. Then, the patient was given an intravenous infusion of 320 mg tocilizumab. The patient’s body temperature dropped to a normal level in a few hours. Within 60 days after the infusion of CAR-T cells, no visceral toxicity and no cytokine release syndrome (CRS) above 3 degrees (NCI-CTCAE standard) were observed (Figure 3). BCR-ABL1 was monitored every 3 months after CAR-T treatment. Unexpectedly, BCR-ABL1 increased from 10.82% (IS) to
Since no other treatment option was available, the patient was given dasatinib (150mg/d) again to determine his sensitivity to dasatinib after CAR-T therapy. To our surprise, it decreased from 70.94% (IS) to 7.27% (IS). By August 27, 2019, the BCR-ABL1 level was still at the level of 0 (Figure 2). Moreover, Sanger sequencing on August 14, 2019 detected no BCR-ABL1 kinase mutation in the patient (Figure 1). No additional chromosomal alterations were identified on September 11, 2019.

Discussion

TKI resistance occurs in more than 25% of CML patients, which is the main reason for disease progression and shortened survival (13). It is related to a variety of mechanisms, among which point mutations in ABL1 kinase region that make TKI unable to bind BCR-ABL1 are the most common reason.17–19 To date, more than 100 emergent mutations have been reported to be related to various degrees of resistance to imatinib.20 Among them,
T315I and P-loop mutations are associated with the highest level of imatinib resistance and the worst clinical outcome.\textsuperscript{21–26} Furthermore, recent studies have shown that about half of the non-responsive patients do not appear to carry \textit{ABL1} kinase mutations.\textsuperscript{27} The involvement of somatic mutations in other genes, such as \textit{DNMT3A},\textsuperscript{28} \textit{ASXL1}\textsuperscript{28} and \textit{RUNX1}\textsuperscript{29–32} may be associated with TKI resistance and progression to advanced stages in CML. Y253H mutation, which developed half a year after imatinib treatment in this case, is located on the P-loop of \textit{BCR-ABL1}. Although it was cleared after the dasatinib treatment, T315I mutation developed subsequently and the patient entered blast crisis phase soon after that. It is possible that Y253H in the P-loop and T315I mutation were the key reason for the patient’s rapid entrance into blast phase.\textsuperscript{33–36} However, since exon sequencing was not performed in this case, there is still a great possibility that other genetic variations led to the rapid disease progression in this patient.

Prior to the TKI era, blast phase was unavoidable. Today, the occurrence of blast phase is about 1% annually,\textsuperscript{37} for which the suggested treatment objective is to either push the disease progression back into the chronic phase or to provide alleviation for the patient. In BP-CML, dasatinib or ponatinib coupled with chemotherapy was suggested to increase the chances of survival and response. However, a study conducted with 477 CML patients in blast phase demonstrated that coupling TKI treatment with intensive chemotherapy yielded the most successful results of 5-year survival rate only of 30%.\textsuperscript{5} In this case, \textit{BCR-ABL1} level decreased significantly after treatment with a combination of dasatinib and chemotherapy. However, \textit{BCR-ABL1} level increased again soon after suggesting that chemotherapy could not overcome the resistance to dasatinib. After anti-CD19 CAR-T cell infusion, the level of \textit{BCR-ABL1} continued to surge to 70.94\% (IS). However, it decreased significantly from 70.94\% (IS) to 0\% (IS) after taking dasatinib again with no mutation detected. It seems that anti-CD19 CAR-T therapy cleared T315I mutation by eliminating CD19\textsuperscript{+} cell clones, which made the patient re-sensitize to the dasatinib.

It is well known that there are at least two groups of cell clones in BP-CML, one in chronic phase and the other in blast phase.\textsuperscript{38} We speculate that the cell clones harboring T315I mutation happen to be the CD19-expressing clones in blast crisis, which were attacked by anti-CD19 CAR-T cells, resulting in the clearance of T315I mutation. Meanwhile, clearance of clones in blast crisis led to the dominant growth of clones in the chronic phase, which led to the large expansion of \textit{BCR-ABL1} expressing cells. This is probably the reason why \textit{BCR-ABL1} increased significantly after CAR-T treatment but decreased prominently after adding dasatinib.

CRS is the most common and serious side effect in CAR-T therapy. It was observed in our patient and was quickly managed. Studies have shown that patients with CRS are more likely to benefit from CAR-T therapy than those without CRS.\textsuperscript{39–41} The tumor loading before CAR-T cell infusion and the expansion of CAR-T cells in vivo are considered to be closely related to the clinical efficacy and severity of CRS.\textsuperscript{42} In this case, dasatinib combined with chemotherapy was given before CAR-T therapy which was helpful to reduce disease burden before infusion. The early use of tocilizumab to inhibit IL-6 also contributed to controlling CRS.
Conclusion
BP-CML with T315I mutation is still challenging even in the TKI era. Combination of anti-CD19 CAR-T therapy with dasatinib successfully cleared the T315I mutation and achieved complete molecular remission in this patient. Therapy regimens to reduce tumor burden and early use of tocilizumab are useful to control CRS without affecting efficacy.

Future Perspective
Immunological abnormality has been described in CML patients at diagnosis and worsens at disease progression. Immunological control may contribute to the achievement of deep molecular response (DMR) and treatment-free remission (TFR). CAR-T cell therapy is a new cell immunotherapy. Patients successfully treated with anti-CD19 CARs often have profound B cell aplasia with some preservation of plasma cells and prior humoral immunity. Furthermore, dasatinib was reported to be associated with beneficial immunomodulatory effects such as increased LGL lymphocytosis and decreased Tregs. Whether the immunomodulatory effect of dasatinib could be changed after CAR-T therapy needs further research.

Informed Consent
The authors state that they have obtained verbal and written informed consent from the patient for the inclusion of their medical and treatment history within this case report.

Ethical Conduct of Research
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330–1340. doi:10.1056/NEJM199904293401706
2. Shivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550–554. doi:10.1038/315550a0
3. Vonck JW, Kaartinen V, Pattengale PK, Germeraad WT, Groffen J, Heisterkamp N. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood. 1995;86:4603–4611. doi:10.1182/blood.V86.12.4603.bloodjournal86124603
4. Burke BA, Carroll M. BCR-ABL: a multi-faceted promotor of DNA mutation in chronic myelogenous leukemia. Leukemia. 2010;24:1105–1112. doi:10.1038/leu.2010.67
5. Chereda B, Melo JV. Natural course and biology of CML. Ann Hematol. 2015;94(Suppl 2):S107–S121. doi:10.1007/s00277-015-2325-z
6. Hatzedagourlu IC. Drug therapy in the progressed CML patient with multi-TKI failure. Mediterr J Hematol Infect Dis. 2015;7:e2015014. doi:10.4084/mjhid.2015.014
7. Jain P, Kantarjian HM, Ghorab A, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients. Cancer. 2017;123:4391–4402. doi:10.1002/cncr.31222
8. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319–325. doi:10.1182/blood.V99.1.319
9. Hofmann WK, Jones LC, Lemp NA, et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood. 2002;99:1860–1862. doi:10.1182/blood.V99.5.1860
10. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet. 2002;359:487–491. doi:10.1016/S0140-6736(02)07679-1
11. Kano Y, Akutsu M, Tsunoda S, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor on preexisting BCR-ABL mutations in chronic myeloid leukemia in children and young adults: a Phase 1 dose-escalation trial. Lancet. 2015;385:517–528. doi:10.1016/S0140-6736(14)61403-3
12. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukemia in children and young adults: a Phase 1 dose-escalation trial. Lancet. 2015;385;517–528. doi:10.1016/S0140-6736(14)61403-3
13. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112:2261–2271. doi:10.1182/blood-2007-12-128843
14. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–733. doi:10.1056/NEJMoa1103849
15. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–448. doi:10.1056/NEJMoa1709886
16. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–2544. doi:10.1056/NEJMoa1707447
17. Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009;27:4204–4210. doi:10.1200/JCO.2009.21.8230
18. Muller MC, Cortes JE, Kim DW, et al. Dasatinib treatment is effective in chronic-phase chronic myeloid leukemia: diagnosis of responses according to preexisting BCR-ABL mutations. Blood. 2009;114:4944–4953. doi:10.1182/blood-2009-04-214221
19. Soverini S, Colarossi S, Gna1i A, et al. Contribution of BCR kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party On Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12:7374–7379. doi:10.1158/1078-0432.CCR-06-1516
20. Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118:1208–1215. doi:10.1182/blood-2010-12-326405
21. Khorasad JS, de Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol. 2008;26:4806–4813. doi:10.1200/JCO.2008.16.9953

22. Nicolini FE, Ibrahim AR, Soverini S, et al. The BCR-ABL T315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013;98:1510–1516. doi:10.3324/haematol.2012.080234

23. Nicolini FE, Corm S, Le QH, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fiphi-LMC GROUP). Leukemia. 2006;20:1061–1066. doi:10.1038/sj.leu.2404236

24. O’Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110:2242–2249. doi:10.1182/blood-2007-03-066936

25. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009;27:469–471. doi:10.1200/JCO.2008.19.8853

26. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol. 2005;23:4100–4109. doi:10.1200/JCO.2005.05.531

27. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006;20:1767–1773. doi:10.1038/sj.leu.2404318

28. Kim T, Tyndel MS, Zhang Z, et al. Exome sequencing reveals DNMT3A and ASXL1 variants associated with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy. Leuk Res. 2017;59:142–148. doi:10.1016/j.leukres.2017.06.009

29. Roche-Lestienne C, Delule L, Corm S, et al. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood. 2008;111:3735–3741. doi:10.1182/blood-2007-07-102533

30. Soverini S, de Benedictis C, Mancini M, Martinelli G. Mutations in the BCR-ABL kinase domain and elsewhere in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):S120–S128. doi:10.1016/j.clml.2015.02.035

31. Growney JD, Shigematsu H, Li Z, et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood. 2005;106:494–502. doi:10.1182/blood-2004-08-2380

32. Zhao LJ, Wang YY, Li G, et al. Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia. Blood. 2012;119:2873–2882. doi:10.1182/blood-2011-08-370981

33. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a Phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22:935–942. doi:10.1200/JCO.2004.03.050

34. Bengio RM, Riva ME, Moiraghi B, et al. Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinian study. Leuk Lymphoma. 2011;52:1720–1726. doi:10.3109/10428194.2011.578310

35. Cho YU, Kim SO, Chi HS, et al. Detection of ABL1 kinase mutations in Philadelphia-positive patients exhibiting an inadequate molecular response using restriction fragment mass polymorphism and its clinical significance: a single-center experience in Korea. Int J Lab Hematol. 2013;35:589–600. doi:10.1111/jjh.12091

36. Elias MH, Baba AA, Azlan H, et al. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome. Leuk Res. 2014;38:454–459. doi:10.1016/j.leukres.2013.12.025

37. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–2417. doi:10.1056/NEJMoa062867

38. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351:657–667. doi:10.1056/NEJMoa040258

39. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28x CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25. doi:10.1126/scitranslmed.3008226

40. Bonati LH, Lobson J, Featherstone RL, et al. Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial. Lancet. 2015;385:529–538. doi:10.1016/S0140-6736(14)61843-3

41. Grupp SA, Koles M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509–1518. doi:10.1056/NEJMoa1215134

42. Park JH, Riviere I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–459. doi:10.1056/NEJMoa1709919

43. Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol. 2010;85:378–398. doi:10.1111/j.1368-816X.2010.03346.x

44. Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010;24:1719–1724. doi:10.1038/leu.2010.185

45. Bhoj VG, Arthoustrongis D, Wertheim G, et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood. 2016;128:360–370. doi:10.1182/blood-2016-01-694356

46. Seggewiss R, Price DA, Partnow MA. Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update. Cytotherapy. 2008;10:633–641. doi:10.1080/14636540802317639

47. Lowe DB, Bose A, Taylor JL, et al. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology. 2014;3:e27589. doi:10.4161/onci.27589

48. Nakaya A, Fujita S, Satake A, et al. Clinical significance of dasatinib-induced pleural effusion in patients with de novo chronic myeloid leukemia. Hematol Rep. 2018;10:7474. doi:10.4081/hr.2018.7474
